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Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease presenting as
sporadic (sALS) or familial (fALS) forms. Even if the list of the genes underlining ALS
greatly expanded, defects in superoxide dismutase 1 (SOD1), encoding the copper/zinc
SOD1, still remain a major cause of fALS and are likely involved also in apparently
sporadic presentations. The pathogenesis of ALS is still unknown, but several lines of
evidence indicate that the mitochondrial accumulation of mutant SOD1 is an important
mechanism of mitochondrial dysfunction, leading to motor neuron pathology and death.
The intramitochondrial localization of mutant SOD1 is debated. Mutant SOD1 might
accumulate inside the intermembrane space (IMS), overriding the physiological retention
regulated by the copper chaperone for superoxide dismutase (CCS). On the other
hand, misfolded SOD1 might deposit onto the outer mitochondrial membrane (OMM),
clumping the transport across mitochondrial membranes and engaging mitochondrial-
dependent cell apoptosis. The elucidation of the mechanisms ruling SOD1 localization
and misplacing might shed light on peculiar ALS features such as cell selectivity and
late onset. More importantly, these studies might disclose novel targets for therapeutic
intervention in familial ALS as well as non-genetic forms. Finally, pharmacological or
genetic manipulation aimed to prevent or counteract the intracellular shifting of mutant
SOD1 could be effective for other neurodegenerative disorders featuring the toxic
accumulation of misfolded proteins.
Keywords: superoxide dismutase 1, motor neuron disorder, mitochondria, mitochondrial intermembrane space,
outer mitochondrial membrane, protein misfolding
Introduction
Amyotrophic lateral sclerosis (ALS) is a lethal neurological disease caused by the selective
degeneration of upper and lower motor neurons, resulting in progressive muscle denervation
and paralysis (Bucchia et al., 2015). Recent studies also feature non-cell autonomous mechanisms
involving contiguous and functionally related cells such as astrocytes, oligodendrocytes, microglia
as well as the extracellular environment (Rizzo et al., 2014). No effective therapy is available for
ALS and understanding the disease pathogenesis could help in developing effective treatments
(Bucchia et al., 2015).
The majority of ALS cases are sporadic (sALS) while familial (fALS) forms account for 10% of
all ALS presentations (Renton et al., 2014). Nevertheless, sALS and fALS share similar phenotypic
features, being clinically indistinguishable, with fALS patients only displaying, sometimes,
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 August 2015 | Volume 9 | Article 336
Tafuri et al. SOD1 mitochondrial misplacing in ALS
earlier onset respect to sporadic probands. To date, the genetic
defect underlining ALS is identified in approximately two thirds
of fALS cases, while nine of ten sporadic forms lack a molecular
diagnosis (Renton et al., 2014). The application of massive
parallel sequencing techniques to undiagnosed cases is expected
to improve the diagnostic yield and the identification of novel
genes in fALS. It is more difficult to predict if sporadic forms
result from undisclosed (rare) molecular defects or are the
consequence of additional factors such as environment and
ageing. Indeed, the existence of multifactorial causes underlining
sALS is a rapidly emerging hypothesis (Robberecht and Philips,
2013). More than 30 genes have been found mutated in ALS
patients but few of them are epidemiologically relevant and
currently considered for genetic testing (Renton et al., 2014).
They include: SOD1, encoding for the copper/zinc superoxide
dismutase 1, TAR DNA binding protein (TARDBP), fused RNA
binding protein (FUS) and C9orf72, containing a pathological
hexanucleotide repeat expansion which constitutes the most
frequent molecular cause of sALS/fALS, towering over all other
defects so far described (Renton et al., 2014).
Despite considerable efforts, the pathogenesis of ALS is still
obscure. Multiple intracellular pathways have been proposed as
relevant: the regulation of RNA transcription and editing, protein
modification, folding and clearance, axonal transport, organelles
maintenance, cell death mechanisms (Robberecht and Philips,
2013; Bucchia et al., 2015; Cozzolino et al., 2015).
The co-existence of multiple abnormalities and the plethora
of results, sometimes contradictory, used to support or
refuse pathogenetic hypothesis give rise to an apparently
‘‘chaotic’’ scenario, reflecting our limited comprehension of
how the identified molecular defects result in motor neuron
pathology and clinical onset. This confusing background
is not surprising since many of the genes involved in
ALS encode for proteins displaying multiple functions. The
intracellular localization of the mutated proteins might also
influence general protein expression and turnover in a cell-
specific manner. In this regard, ALS has been considered a
polygenic and multifactorial disorder, where derangement of
multiple pathways might produce similar phenotypes sharing
clinical, instrumental, and prognostic features (Robberecht and
Philips, 2013). Since fALS and sALS also share common
defects and similar alterations have been found in ALS
animal models and patients’ tissues, the existence of conserved
mechanisms underlining motor neuron pathology has been
proposed.
SOD1 mutations have been the first molecular defects
described in fALS forms with dominant inheritance (Rosen
et al., 1993) and most of the research studies addressing ALS
pathogenesis and the development of therapeutic strategies
have been performed using SOD1 transgenic models (Gurney
et al., 1994). Recent discoveries in ALS genetics acknowledge
the role of proteins involved in RNA metabolism and
cytoskeletal organization, often enriched in central nervous
tissues. Conversely, the expression of SOD1 is ubiquitous
and not restricted to nor increased in spinal cord and
motor neurons. Further, SOD1 levels are not developmental-
regulated. SOD1 enzyme shows a single, well-defined catalytic
function, dealing with the detoxification of the superoxide
specie inside cells. In the hunt for the ALS culprit, the
loss of SOD1 enzymatic activity has been rapidly ruled
out, since mutations preserving or abolishing SOD1 activity
were found to cause ALS (Cozzolino et al., 2015). These
elements alone indicate that the involvement of SOD1 in an
adult onset motor neuron neurodegenerative disorder is not
obvious.
The seminal observation of the co-localization of SOD1 with
vacuolated mitochondria in a mouse model expressing human
mutant SOD1 (Jaarsma et al., 2001) advanced the hypothesis
that SOD1 mutations might be toxic for mitochondria. These
studies have been replicated and expanded in several experiments
performed in tissues and cells obtained from ALS animal models
and patients (Palomo and Manfredi, 2015). Mitochondrial
impairment has been observed in major neurodegenerative
disorders (Schon and Przedborski, 2011). Although motor
neurons are highly reliant on oxidative phosphorylation, the
relevance of mitochondria in ALS pathogenesis has been under
evaluated for many years. However, signs of mitochondrial
dysfunction have been observed in multiple ALS patients
(Cozzolino et al., 2015) and tissues, including muscle (Corti
et al., 2009). In a review of a large series of muscle biopsies, we
found that respiratory chain impairment is a common feature of
ALS muscles, sometimes preceding the motor neuron pathology
(Crugnola et al., 2010), consistent with experimental models (Luo
et al., 2013).
Differently from Parkinson’s disease (PD), where several
genes involved in familial forms encode for mitochondrial
proteins (De Rosa et al., 2015), the mitochondrial localization
of products encoded by ALS-related genes is not exclusive.
We previously described an out-of frame mutation in the
gene encoding for a mitochondrial subunit of cytochrome
c oxidase (COX) in a patient with severe muscle COX
deficiency and a clinical phenotype resembling ALS (Comi
et al., 1998). Similarly, primary mitochondrial disorders might
present as motor neuron phenotypes (Ronchi et al., 2012).
Recently, a missense mutation in CHCHD10, encoding for
an intermembrane space (IMS) protein likely involved in
mitochondrial cristae remodelling, was found to segregate
with disease in a large French family displaying ALS with
frontotemporal dementia (Bannwarth et al., 2014). Although
additional CHCHD10 mutations were detected in patients with
motor neuron disorders (Cozzolino et al., 2015), mitochondrial
dysfunction has been only occasionally documented (Ronchi
et al., 2015).
Physiologically, a small proportion of SOD1 protein is
located in the mitochondrial IMS of yeast (Sturtz et al.,
2001) and mammals (Okado-Matsumoto and Fridovich, 2001;
Figure 1A). A protective antioxidant role for mitochondrial
SOD1 has been hypothesized (Okado-Matsumoto and Fridovich,
2001) although without conclusive evidences. Conversely,
whether SOD1 mutants accumulate inside mitochondria and
the consequence of such accumulation have been largely
investigated. Although aberrant SOD1 was observed within
mitochondrial matrix (Vijayvergiya et al., 2005), two main
submitochondrial localizations for mutant SOD1 are generally
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FIGURE 1 | SOD1 function and structure. (A) Electron transport chain
locatedin the inner mitochondrial membrane (IMM). (1) and (2) represent the
main sources of superoxide anion (O2−), a reactive oxygen specie converted
to H2O2 in a dismutase reaction catalyzed by SOD (Cu/Zn; SOD1) and SOD
(Mn; SOD2) in the intermembrane mitochondrial space (IMS) and matrix,
respectively. C I: complex I NADH dehydrogenase. C II: complex II succinate
dehydrogenase. C III: complex III ubiquinol cytochrome C oxidoreductase.
C IV: complex IV cytochrome C oxidase. C V: complex V ATP synthase.
(B) Scheme representing the determinants of tertiary structure of human
SOD1, including β sheets (green arrows), α helix (yellow cilinder) and loops. β
sheets: β1: 2–8◦ aa -β2: 15–22◦ aa -β3: 29–36◦ aa -β4: 41–48◦ aa -β5:
83–89◦ aa -β6: 95–101◦ aa -β7: 116–120◦ aa -β8: 143–151◦ aa. α helix:
134–137◦ aa. The yellow dots represent residues involved in Cu2+
coordination (His46, His48, His63, His120). The orange dots represent
residues involved in Zn2+ coordination (His63, His71, His80, Asp83). The
purple dots represent residues involved in disulfide bridge formation (Cys57,
Cys146).
acknowledged: the IMS and the outer mitochondrial membrane
(OMM). In this review, we focus on the pathogenetic role
of mutant SOD1 elicited by its misplacing in mitochondria,
depicting the pathways ruling its targeting towards IMS or
OMM. We will also comment on how these events relate
to ALS pathogenesis, including cell selectivity and age of
onset.
Mitochondrial Localization of Non-Mutated
SOD1
Human SOD1 maps to chromosomal location 21q22.11 and
encodes for a 17 kDa protein (Figure 1B). The encoded
product, SOD1, is an enzyme which catalyses the removal
of superoxide according the reaction O2− + 2H+ → H2O2
(superoxide dismutation). Human genome encodes for two
additional superoxide dismutases: SOD2, located inside
mitochondrial matrix and the extracellular SOD3. There
is no apparent evolutionary relationship between SOD1
and its isoenzymes. SOD1 is generally acknowledged as a
cytosolic enzyme (Vehviläinen et al., 2014), but it is now
accepted that a minor fraction (less than 5%) of total SOD1
can be found in the IMS, in lower (Sturtz et al., 2001)
and higher eukaryotes (Okado-Matsumoto and Fridovich,
2001).
Mitochondrial respiratory chain, assembled inside the inner
mitochondrial membrane (IMM), produces high amounts of
reactive oxygen species (ROS) as a bypass product of the
electron transfer reactions occurring in respiratory chain
complexes (mainly complex I and complex III; Murphy, 2009).
The release of superoxide anion on both sides of the inner
membrane requires dedicated detoxification enzymes inside
mitochondrial matrix (SOD2) and IMS (SOD1). Reactions
catalysed by SOD enzymes result in the production of
H2O2, another dangerous ROS able to react with Cytochrome
C (Fe3+) producing the highly reactive species Oxoferryl-
CytC CytC (Fe4+; Vehviläinen et al., 2014). Therefore H2O2
must be carefully neutralized and cells express catalase,
glutathione peroxidase and peroxiredoxins to process H2O2
(Palomo and Manfredi, 2015). It has been proposed that,
under mitochondrial stress, exceeding SOD1 activity might
paradoxically boost the production of toxic ROS inside
IMS by increasing H2O2 production and consequently the
deleterious cytochrome-c mediated peroxidation (Goldsteins
et al., 2008).
To work properly, SOD1 requires post-translational
modifications including the formation of intramolecular
disulfide bonds to achieve a correct folding, the binding of zinc
and copper metal ions, and the exposition of a hydrophobic
region required for the organization of SOD1 monomers in
dimers. These post-translational changes not only are necessary
for SOD1 function but also influence its subcellular localization
(Figure 2). Despite the lack of a mitochondrial localization
signal, after cytosolic translation, a small amount of SOD1
might enter mitochondria in an unfolded state, taking advantage
of the OMM translocator TOM (Kawamata and Manfredi,
2008; Figure 3A). The copper chaperone for superoxide
dismutase (CCS) promotes the establishment of disulfide
bonds and catalyses the insertion of copper metal into SOD1
apoenzyme (Culotta et al., 1997). After reaching its mature form,
SOD1 also remains inside IMS, with coordinated metals and
disulfide bonds now preventing the leakage back to the cytosol
(Kawamata and Manfredi, 2008). CCS greatly contributes to
SOD1 entrapment inside IMS through the establishment of a
disulfide bond between cysteines C57 and C146 and favoring the
copper insertion into the apoenzyme (Kawamata and Manfredi,
2008).
CCS has been also postulated to act as a redox sensor
for the subcellular distribution of SOD1. High cytosolic
oxygen concentration maintains CCS in the cytosol where
it folds and helps apoenzyme SOD1 to achieve a mature
form. Low oxygen concentrations (hypoxia) promote the
translocation of CCS across the mitochondrial membrane. Inside
IMS, CCS induces the oxidative (disulfide bonds) folding of
SOD1 apoezyme and inserts the copper. The rationale for
this mechanism is that the expected boost of mitochondrial
respiratory chain activity, induced by hypoxia, will increase
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FIGURE 2 | Transport of SOD1 across mitochondrial intermembrane
space (IMS). SOD1 (unfolded) apo-protein enters IMS through the
transporter of outer membrane (TOM). Inside IMS unfolded SOD1
undergoes maturation steps: (1) disulfide bonds promoting a proper
folding, (2) the insertion of metal ions Zn and Cu, (3) dimerization.
Disulfide bonds formation and prosthetic group insertion are mediated by
copper chaperone for superoxide dismutase (CCS). Disulfide bonds
prevent SOD1 leakage from mitochondria through TOM. High O2 levels
might also induce CCS and SOD1 protein folding in cytoplasm. SOD1,
superoxide dismutase 1; CCS, copper chaperone for superoxide
dismutase; TOM, translocase of outer membrane; OMM, outer
mitochondrial membrane; IMS, intermembrane space.
the concentration of superoxide anion inside mitochondria: the
enhanced translocation of CCS, promoting SOD1 maturation,
might be part of a compensatory antioxidant strategy (Kawamata
and Manfredi, 2008). Therefore the intracellular distribution
(and activation) of SOD1 is intimately related to the intracellular
location of its chaperone CCS. CCS also lacks a canonical
mitochondrial localization signal and relies for its mitochondrial
import on the so-called disulfide relay system (DRS), classically
used by small cysteine-rich IMS proteins (Mesecke et al.,
2005). This mechanism, identified in yeast 10 years ago
(Mesecke et al., 2005), is quite conserved across evolution
(Fischer and Riemer, 2013). The IMS proteins MIA40 and
ERV1 are key players of this folding trap mechanism. When
a substrate of the DRS, like apo-CCS, enters the IMS, it
undergoes a MIA40-mediated oxidation involving the shifting
of disulfide bonds between specific cysteine pairs (disulfide
relay). This oxidation-mediated folding retains the DRS substrate
inside IMS (Herrmann and Riemer, 2010). MIA40, now
reduced, is re-oxidized by ERV1/ALR, a FAD-dependent
sulfhydryl oxidase that transfers electrons to cytochrome C
(Herrmann and Riemer, 2010). Therefore, respiratory chain
is connected with the DRS, influencing the import of several
mitochondrial proteins, including assembly factors involved in
the assembly of respiratory chain and the maturation of inner
membrane.
Several authors have demonstrated that CCS is a substrate
of DRS, differently from SOD1 (Groß et al., 2011; Klöppel
et al., 2011). However, a recent observation proposed that
MIA40 is dispensable for oxidation-dependent import
of CCS into mitochondria: CCS might directly promote
its own oxidation, as well as the oxidation of SOD1 and
other, still uncharacterised, substrates (Suzuki et al., 2013).
These findings reinforce the link between SOD1 and its
chaperone CCS in terms of activity and subcellular distribution.
Interestingly, an alternative pathway for SOD1 mitochondrial
translocation has been depicted in yeast, acknowledging the
role of mitochondrial inner membrane organizing system
(MINOS; Varabyova et al., 2013). The MINOS machinery
is a recently identified protein complex involved in the
organization of the IMM (Varabyova et al., 2013). Notably,
CHCHD10 may be part of this complex, given its apparent
function and structural similarities with other members of
the MINOS system. Although the underlining mechanism is
still unclear, the mitochondrial import of SOD1 is reduced
in yeast mutants lacking MINOS core components. MIA40
is also fundamental for this alternative import pathway
with a different role respect to that of oxidation scaffold
described in the DRS (Varabyova et al., 2013). The dysfunction
of DRS pathway and MINOS machinery result in clinical
phenotypes with mitochondrial impairment as observed
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 August 2015 | Volume 9 | Article 336
Tafuri et al. SOD1 mitochondrial misplacing in ALS
FIGURE 3 | Accumulation of mutant SOD1 inside IMS and
deposition onto OMM. (A) Mutant SOD1 enters IMS through TOM.
Inside IMS mutant SOD1 can precipitate in insoluble form (1) or
undergo folding via Mia40 resulting in the establishment of funtional
homodimers and heterodimers (2). Mia40 transfers electrons to
Cytochrome C (CytC) via Erv1 (3). TOM, translocase of outer
membrane; OMM, outer mitochondrial membrane; IMS,
intermembrane space; IMM, inner mitochondrial membrane; CIV,
complex IV cytochrome C oxidase; MutSOD1, mutant SOD1.
(B) Misfolded SOD1 localization upon mitochondria can be regulated
in different tissue cells. Cytosol composition may differ according cell
types. High cytosolic levels of soluble MIF (macrophage migration
inhibitory factor) are able to prevent SOD1 mislocalization where its
absence favor SOD1 deposition onto OMM. Misfolded SOD1
interactions with OMM proteins, such as Bcl-2 and VDAC, activate
pro-apoptotic mitochondrial pathway leading to cell death. This
interaction can be prevented by MIF. TOM, translocase of outer
membrane; OMM, outer mitochondrial membrane; IMS,
intermembrane space; IMM, inner mitochondrial membrane; CIV,
complex IV cytochrome C oxidase; MutSOD1, mutant SOD1.
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in patients harbouring mutations in core components
(Di Fonzo et al., 2009) or substrates (Bannwarth et al., 2014) of
these mechanisms.
Accumulation of Mutant SOD1 in the
Mitochondrial Intermembrane Space (IMS)
More than 150 SOD1 mutations have been associated with
ALS, the large part being point mutations leading to amino
acid substitutions (Synofzik et al., 2012). SOD1 mutations are
dominantly inherited although recessive inheritance has been
also described, especially for those variants that show low
penetrance.
Accumulation, misfolding, aggregation, and precipitation of
proteins seem to be common hallmark of neurodegenerative
disorders (Taylor et al., 2002). SOD1 mutants so far analysed
show different properties on the basis of the residues affected. As
an example, several SOD1 mutants display no catalytic activity
while dismutase activity is totally preserved in G93A, likely
the most investigated of the ALS mutations. The conservation
of catalytic activity seems also to reflect the conservation of
a proper folding, assayed, before the advent of conformation
specific antibodies (Rotunno and Bosco, 2013), by resistance to
proteinase K digestion.
Different mutations might also show different propensities to
accumulate or to aggregate in high molecular weight complexes.
Presence of aggregates of mutated proteins in motor neurons
is increasingly considered as a hallmark of ALS. Furthermore,
a relationship between insoluble mutant SOD1 aggregates
and expression of signs/symptoms has been demonstrated in
many different rodent models (Johnston et al., 2000; Wang
et al., 2002, 2003) in line with human findings (Kato, 2008).
Despite considerable study, the mechanism that confers to
SOD1 aggregates cell toxicity is still undefined. It has been
hypothesized that mutant SOD1 soluble species are responsible
for the disease onset (Zetterström et al., 2007; Karch et al.,
2009) being, indeed, more toxic than insoluble aggregated
SOD1 forms (Zetterström et al., 2007; Brotherton et al., 2012;
Weichert et al., 2014). The intriguing problem of SOD1
aggregation is further complicated by the fact that experimental
studies have been largely performed in lines of transgenic
animals (or motor neuronal cells) with strong, although
heterogeneous, overexpression of mutant proteins required to
display pathological phenotype. The lack of physiological SOD1
expression and the underestimated expression of wild type
alleles (normally present in almost all ALS patients) challenge
the results obtained in these studies. The replication of these
experiments in a patient-specific context might overcome these
limitations.
Other manifestations of SOD1 mutations are protein
misfolding and intracellular mislocalization. Soluble misfolded
mutant SOD1 was found augmented in the mitochondria of
the ALS spinal cord rodents (Zetterström et al., 2007), and
the specific conformation of these forms could enhance their
mitochondrial entrance. Antibodies that selectively recognize
misfolded/non-native SOD1 have pointed out the link between
misfolded SOD1 and mitochondria in the spinal cord of ALS
rodents expressing human mutant SOD1 (Vande Velde et al.,
2008; Brotherton et al., 2012). SOD1 misfolding seems to be
related to different post translational mechanisms, involving
disulfide bridge formation (Karch et al., 2009; Kawamata and
Manfredi, 2010), incorrect C6 and C111 bond (Niwa et al.,
2007) and loss of metal ion binding (Banci et al., 2008). These
abnormal functions lead to altered SOD1 dimerization and to
a biochemically instable tertiary structure (Banci et al., 2008,
2012). Several SOD1mutants show instability in vitro (Rodriguez
et al., 2002, 2005; Lindberg et al., 2005) or are found in a
partially unfolded oligomerized status in mitochondria (Deng
et al., 2006; Ferri et al., 2006). Remarkably, Synofzik et al. (2012)
described a family showing slowly progressive ALS phenotype
due to the L117V SOD1 mutation, which is similar to wild type
SOD1 respect to stability and dismutase activity. These data
are in line with previous findings reporting that even minor
quantities of misfolded SOD1 are sufficient to prompt ALS
(Jonsson et al., 2006). Indeed, overexpressed wild type SOD1
is capable to achieve an unstable (misfolded) state, causing
motor neuron disease phenotype in rodents (Graffmo et al.,
2013).
ALS-linked SOD1 mutations might also affect mitochondrial
localization, facilitating the crossing of the OMM. Indeed,
demetalated or unfolded SOD1 enzymes due to inefficient
cytosolic maturation caused by ALS mutations might increase
the fraction of intramitochondrial SOD1 (Field et al., 2003).
Similarly, increased mitochondrial accumulation of SOD1 (both
wild type and mutant) was observed in vitro after experimental
copper depletion (Arciello et al., 2011).
The accumulation of SOD1 in mitochondria of motor
neurons has been proposed as a possible explanation for the
selective motor neuron degeneration occurring in ALS (Bruijn
et al., 2004). Indeed, several groups have reported that mutant
SOD1 co-localizes with mitochondria by immunocytochemical
and biochemical studies. Although not exclusive, brain, spinal
cord and motor neurons seem to be particularly exposed
to mutant SOD1 accumulation and sensitive to the resulting
mitochondrial dysfunction (Jaarsma et al., 2001; Higgins et al.,
2002; Mattiazzi et al., 2002; Sasaki et al., 2004; Ahtoniemi et al.,
2008). Notably in most of the experiments, the accumulation of
SOD1 inside mitochondria paralleled the disease progression.
Forcing the expression of constructs containing wild type
and mutant SOD1 in different cellular compartments of
a mouse neuroblastoma cell line resulted in increased cell
death and mitochondrial dysfunction only when mutant
species were targeted to mitochondria (Takeuchi et al.,
2002). Specifically, the accumulation of SOD1 in IMS
seems toxic. In cultured motor neuronal cells, obligate
SOD1 expression in IMS leads to mitochondrial toxicity and
cell death, giving results not dissimilar to those collected
expressing untargeted SOD1 mutants (Cozzolino et al.,
2009; Magrané et al., 2009). Although the mitochondrial
environment induced abnormal oligomerization of wild type
SOD1, mutant SOD1 tends to form insoluble aggregates
inside mitochondria, leading to alterations in mitochondrial
morphology, function and engagement of apoptosis. The
removal of the cysteines involved in disulphide bond by genetic
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 August 2015 | Volume 9 | Article 336
Tafuri et al. SOD1 mitochondrial misplacing in ALS
manipulation counteracted these changes (Cozzolino et al.,
2009).
A mouse line expressing G93A SOD1 mutant targeted
to IMS displayed neurological deficits although less evident
compared to classical G93Amousemodel (lackingmitochondrial
targeting but presenting a stronger expression of the transgene;
Igoudjil et al., 2011). Interestingly, the selective targeting of wild
type SOD1 in IMS of the knockout SOD1 mouse prevented
the development of motor neuropathy and preserved axonal
maintenance. The rescue effect was associated with reduced
oxidative stress inside mitochondrial compartment (Fischer
et al., 2011).
The groups of Jeffrey Elliot and Giovanni Manfredi authored
several articles about the aberrant accumulation of mutant
SOD1 inside mitochondrial IMS. First, Elliot’s team observed
that G93A mice developed accelerated neurological deficits
when crossed with lines overexpressing CCS in CNS tissues.
The double transgenic also displayed a striking reduction
of age at onset and lifespan. Protein studies revealed a
significantly increased of mitochondrial SOD1 content.
Consistently, the dual transgenic mice expressing wild type
SOD1 did not show any abnormalities with the exception
of a modest increase of mitochondrial SOD1 import. Mouse
overexpressing CCS displayed a normal phenotype, rejecting
the hypothesis that an overloaded DRS was at the basis of
the observed mitochondrial dysfunction. Notably the genetic
ablation of CCS did not prevent motor neuron phenotype and
mitochondrial accumulation of mutant SOD, supporting the
existence of alternative pathways for mitochondrial import
of SOD1 (Son et al., 2007). The impressive phenotypic effect
of CCS overexpression in presence of G93A SOD1 does not
seem related to SOD1 misfolding or aggregation. The G93A
substitution makes SOD1 a less adequate substrate for CCS,
preserving the physical interaction with the chaperone but
impairing proper oxidative folding and metallation (Proescher
et al., 2008). Notably, the levels of COX activity and assembly
as well as protein levels of COX-subunits were selectively
reduced in spinal cord from transgenic mice, even at a
pre-symptomatic stage (Son et al., 2008) likely reflecting a
disturbance in COX maturation. This finding demonstrates
that the abnormal mitochondrial translocation of mutant
SOD1 might affect respiratory chain, hindering mitochondria
from inside. However, the same authors demonstrated that
the functional and biochemical defects caused by CCS
overexpression depend upon the redox state of the SOD1
mutant: while G37R paralleled the findings of G93A mutation,
other substitutions (G86R and L126Z) did not (Son et al.,
2009). These results had been partially anticipated by in vitro
studies of Ferri et al. (2006) who had observed a shifting of the
redox potential of several SOD1 mutants inside mitochondria.
Interestingly, the manipulation of redox state of mitochondrial
environment by overexpression of antioxidant enzymes
glutaredoxin 1 and 2 improved SOD1 solubility and reduced
mitochondrial anomalous localization (Cozzolino et al.,
2008; Ferri et al., 2010). In particular, increased activity of
glutaredoxin 2 inside mitochondrial matrix prevented the IMS
aggregation of insoluble mutant SOD1 (Ferri et al., 2010).
The functional rescue of mitochondria is likely mediated by
a general antioxidant pro-survival effect of glutaredoxin 2
not requiring a direct interaction with mutant SOD1: indeed,
glutaredoxin 2 and SOD1 show a different intramitochondrial
segregation.
Kawamata and Manfredi (2008) used mammalian cells to
confirm that SOD1 subcellular distribution is driven by CCS
in vitro. They also highlighted the importance of cysteine
residues in the CCS-mediated oxidation of mutant and wild
type SOD1. Finally, they found that toxic properties of mutant
SOD1, including propensity to aggregate and misfolding,
could override CCS-dependentmitochondrial recruitment. Once
inside IMS, mutant SOD1 can preserve its soluble form and
build up homo and heterodimers with wild type SOD1 or
aggregate with other mutant proteins and precipitate in insoluble
form. According to SOD1 mutation, one way will prevail on
the other; nevertheless, these aspects are not predictive of
clinical phenotype (Vehviläinen et al., 2014). The untargeted
overexpression of CCS in motor neuron-like cells improved the
solubility of cytosolic mutant SOD1 and increased the formation
of insoluble aggregates of G93A SOD1 targeted to mitochondrial
compartment (Cozzolino et al., 2009). The mitochondrial import
of mutant SOD1 was enhanced by exposing NSC34 cells to
inflammatory cytokines, supporting the existence of not-cell
autonomous factors able to influence SOD1 localization (Ferri
et al., 2008). Therefore, mutant SOD1 may escape physiological
control of mitochondrial localization, performed by CCS,
and remain inside mitochondria exerting toxic effects. CCS
translocation into mitochondria might help to entrap mutant or
wild type SOD1 enzymes inside IMS, without any influence on
their transport across the OMM.
Deposition of Mutant SOD1 Onto the
Cytoplasmic Layer of Outer Mitochondrial
Membrane (OMM)
The results so far presented demonstrate that both wild
type and mutant SOD1 can be recovered by mitochondrial
fractions of ALS animal and cell models. It is likely that the
final submitochondrial location of SOD1 is the IMS and that
different pathways (dependent or not on CCS) might influence
this subcellular repartition. Moreover, it is conceivable that
mutant SOD1 can aggregate into the IMS, as in the cytosol,
contributing to mitochondrial dysfunction. Interestingly, mutant
SOD1 aggregation was also observed in the mitochondrial matrix
of two transgenic mice lines and the recovered SOD1 resulted less
active and folded respect to cytosolic counterpart (Vijayvergiya
et al., 2005). However, mitochondrial matrix has not been further
investigated as a target for mutant SOD1 toxicity in other ALS
models.
While both mutant and wild type enzymes have been
observed inside mitochondria, the OMM has been proposed to
be a more selective target for mutant SOD1 only, explaining
crucial aspects of ALS pathology such as cell selectivity and
symptoms onset. Two research groups have mainly contributed
to this topic. Pasinelli et al. (2004) used immunoprecipitation
studies to demonstrate that SOD1 associates with the OMM
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protein Bcl-2 in the mitochondrial fractions obtained from
cells expressing wild type and mutant SOD1. These findings
were also confirmed in vivo. Wild type and mutant SOD
interacted with different domains of Bcl-2 protein. Indeed,
the authors showed that mutant SOD1 alters the physiological
SOD1/Bcl-2 binding and primes the formation of high molecular
weight complexes containing SOD1 and Bcl-2. Interestingly,
experiments performed on G93A mice and autoptic samples
from a patient harbouring the A4V SOD1 mutation showed
that Bcl-2 is selectively sequestered by mutant SOD1 in
mitochondria isolated from spinal cord, but not liver (Pasinelli
et al., 2004). In a back-to-back paper, Don Cleveland’s team
supported these findings. Mutant SOD1 was preferentially
recovered in the mitochondrial fraction purified by gradient
centrifugation of spinal cord mitochondria from symptomatic
animal models expressing mutant (G93A) but not wild type
SOD1 (Liu et al., 2004). Mutant SOD1 was absent in
mitochondrial preparations obtained from other tissues. The
effect of CCS on mitochondrial distribution was ruled out
by genetic ablation of this gene. The preferential association
of mutant SOD1 with spinal cord mitochondria was also
confirmed in autoptic samples, taking advantage of a selective
antibody developed to recognize the epitope created by a SOD1
truncating mutation. In a second series of experiments, the
authors isolated floating mitochondria, excluding the chance
of co-precipitation or co-sedimentation of interfering SOD1
located inside cytosol or other organelles (Vande Velde et al.,
2008). Again, they observed that SOD1 selectively tightly
associate with mitochondria from spinal cord (not the brain)
in transgenic mice in an age-dependent manner. Using alkali-
based extraction protocol they investigate the nature of this
association. Exploiting an antibody developed to decorate only
the misfolded fraction of SOD1, they conclusively observe
that the mutant SOD1 associated with mitochondria is in its
misfolded state, while the remaining folded protein contribute
to cytosolic or mitochondrial (IMS) SOD1 content. They
proposed the voltage-dependent anion channel (VDAC) channel
(mitochondrial porin) as the candidate docking protein for
misfolded SOD1 deposition onto OMM. VDAC was found to
co-precipitate only with misfolded SOD1. Symmetrically, mutant
SOD1 deposited on VDAC only when inserted in the cytosolic
face of a membrane reconstructed in vitro (Israelson et al.,
2010).
The experiments discussed so far supports the selective
targeting of spinal cord mitochondria and the existence of an
interaction between SOD1 and OMM proteins (Figure 3B).
However, the specific target of SOD1 onto OMM (Bcl-2 vs.
VDAC1) and the SOD1 specie involved in this interaction
(mutant only or wild type and mutant) differed according
the two groups of investigators and were object of further
studies.
Bcl-2 is an integral OMM protein, while VDAC1 is a
mitochondrial voltage-dependent ion channel: both are involved
in the intrinsic apoptotic process. Bcl-2 regulates the release of
cytochrome c by the mitochondrial channel VDAC (Shimizu
et al., 1999) and inhibits proapoptotic Bax signaling. Bcl-2 has
been proposed as a direct mediator of mitochondrial toxicity
of mutant SOD1 since it is required to induce cytochrome c
release and change in mitochondrial morphology upon exposure
to mutant, but not wild type, SOD1. Notably, this effect
was only observed if Bcl-2 was tethered to OMM (Pedrini
et al., 2010). The authors demonstrated in vitro and in vivo
that mutant SOD1 alters Bcl-2 conformation, exposing its
BH3 (death) domain, without which the toxic effect was
ineffective.
VDAC1 acts as a gate for ions, metabolites, nucleotides,
in two different dynamic conformation states. While open it
allows anions, ATP and succinate flow from mitochondria
to cytoplasm; when VDAC1 is closed it acts as a small
cations channel. The impairment in VDAC1 function has been
also linked with mitochondrial dysfunction since the drop of
ATP/ADP ratio and membrane potential drives the increase of
ROS production, hence contributing to extend the amount of
misfolded SOD1 (Vande Velde et al., 2008; Israelson et al., 2010).
Mass spectrometry analysis revealed more widespread changes
in mitochondrial protein composition and significantly reduced
mitochondrial import (Li et al., 2010).
We must observe that mitochondria from different tissues
have different protein repertoires. This is true for OMM (Mootha
et al., 2003; Bailey et al., 2007), which is also exposed to different
cytoplasm compositions (Boillée et al., 2006; Vande Velde et al.,
2008; Israelson et al., 2015). Tissue type, epigenetics regulation,
gene transcription, oxygen concentration and ROS production
may contribute to the specification of proteins recruited onto
OMM (Israelson et al., 2010). Even considering these aspects, it is
difficult to think at VDAC as a selective target for mitochondrial
deposition of mutant SOD1 in spinal cord motor neurons, since
it is widely expressed. Moreover, protein trafficking across OMM
is partially rescued by other members of the VDAC family
including VDAC2 and VDAC3. The hypothesis of a direct
interaction between mutant SOD1 and VDAC has been recently
challenged (Tan et al., 2013). According these observations,
collected in vitro and in vivo, VDAC dysfunction is the result
of a toxic association between mutant SOD1 and Bcl-2. Both
SOD1 and VDAC compete for Bcl-2, which acts as a bridge
between the two proteins. The conformational change in Bcl-2,
induced by mutant SOD1 binding, exposes the toxic BH3
domain and favors the association of modified Bcl-2 with VDAC,
resulting in a pathological alteration of OMM polarity and
permeability, due to VDAC closure. This stream of mismatch
associations seems to be a key event in disease initiation and
progression. Interestingly, the administration of small peptides
designed to target SOD1 and blocking its interaction with
Bcl-2 might counteract these pathological alterations (Tan et al.,
2013).
Collectively, the consequence of mutant SOD1 deposition
onto OMM are: (i) conformational change of Bcl-2 preventing its
anti-apoptotic association with Bax; (ii) impairment of VDAC1
function engaged by direct (SOD1-mediated) or indirect (Bcl-
2 mediated) abnormal interactions with mutant SOD1, leading
to changes in mitochondrial potential, morphology, protein
composition and transport across membranes.
The specificity of mutant SOD1 in OMM targeting seems to
be dictated by factors contained in the cytosol of the considered
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cell rather than its mitochondria. From these considerations, two
hypotheses raised: it may exist a factor in spinal motor neurons
that favors mislocalization, or, alternatively, there is a factor in
the cytosol of other cells preventing it (Israelson et al., 2015). In
a very recent publication, Cleveland investigated different heat
labile factors that can block SOD1 mitochondria accumulation,
selecting MIF as the most promising candidate. MIF (22q11.23)
encodes for a small (12.5 kDa) protein, displaying multimeric
and monomeric forms, with various functions: folding ATP-
indipendent chaperone, thiol-oxidoreductase, and secreted
cytokine.
MIF interacts with mutant SOD1 by preventing its binding
with OMM proteins and the accumulation of misfolded SOD1.
Other chaperones (Hsp70, Hsc70, aB-crystallin, cyclophilin-
A, glutathione peroxidase) had no effect in blocking SOD1
misplacing onto mitochondria outer membrane (Israelson et al.,
2015). The inhibitory activity of MIF is preserved even in mutant
lacking thiol-oxydoreductase activity. This is an important
consideration since misfolding and mislocalization are supposed
to be driven by the lack of C57-C146 bond (Vehviläinen et al.,
2014) and by mitochondrial binding induced by C111 (Ferri
et al., 2006), respectively.
At onset, SOD1 G93A mice showed reduced MIF levels
in motor neurons as an effect of rapid protein clearance
(given the demonstration of conserved MIF transcription and
active translation): the restoration of MIF to normal levels
enhanced motor neurons survival. Since reducing misfolded
SOD1 aggregates does not halt disease progression, in vivo
toxicity seems to be driven by solublemisfolded SOD1, which can
be reduced by the increase of MIF in a dose-dependent manner
(Israelson et al., 2015).
The results presented about the toxic deposition of misfolded
SOD1 onto OMM and those coming from the identification
of MIF as the soluble factor responsible for the selective
neutralization of misfolded SOD1 are intriguing. In particular,
the misfolded accumulation of mutant SOD1 seems to be
conserved in both active and inactive mutants, the latter
presenting greater amount of misfolded proteins. This finding
nicely fits with a general observation about the more aggressive
phenotype (earlier onset, faster progression) associated with
inactivating mutations (Sato et al., 2005). At the same time,
even small amount of mutant misfolded proteins might
produce a clinical phenotype in human while high levels
of expressions of mutant constructs (different according the
mutations considered) are required to show a neurologic deficit
in mice.
More importantly, these studies provide novel clues about the
selectivity of spinal cord involvement and disease progression.
These results were confirmed and refined in independent
experiments, although the same authors disclosed misfolded
SOD1 in mitochondrial fractions isolated from patients’
lymphoblasts, challenging the cell type selectivity (Pickles et al.,
2013). The identification of MIF as a candidate for ALS
therapy is an intriguing discovery but this story is at its dawn.
More confirmations are required to address unresolved issues
including investigations on the degradative or secretive pathways
acting in motor neurons to deprive intracellular MIF levels.
Conclusion
Several groups demonstrated positive correlation between
mutant SOD1 and ALS and the main pathogenetic hypothesis
is a toxic gain of function. What is the toxic function gained
and why it selectively strikes spinal motor neurons is still
unexplained, but certainly not unexplored. One of the most
investigated pathogenetic hypothesis underlining SOD1-related
ALS focuses on mitochondrial toxicity of mutant SOD1. Fifteen
years after the first observation on the co-localization of mutant
SOD1 with vacuolated mitochondria in G93A mice spinal cord,
the issue of SOD1 localization generated contradictory results
but also promising answers. The mitochondrial localization of
wild type and mutant SOD1 is a result definitively acquired
and the hypothesis that the mutant function associated with
ALS mutations involves the aberrant processing of superoxide
anions is considered unlikely. Two major models have been
advanced for mutant SOD1 accumulation inside mitochondria:
increased content of mutant molecule, escaping physiological
regulation inside IMS and selective deposition of misfolded
protein onto OMM. These two routes are not mutually exclusive
and studies supporting one model have also acknowledged the
other as possible. The issue of submitochondrial localization
hidden more relevant questions: which are the factors involved
in SOD1 targeting towards mitochondria? Is the toxicity of
mutant protein linked with aggregates (cytosolic or IMS), or
soluble forms (SOD1 neutralized by MIF inside cytosol)? Are
the mitochondria central for downstream ALS pathogenetic
events or mitochondrial dysfunction adds to other intracellular
mechanisms leading to motor neuron loss? Despite its key role
in metabolism, mitochondria are involved in other fundamental
cellular pathways, including calcium handling. Neuroblastoma
cells expressing SOD1mutants show higher levels of intracellular
calcium compared to controls and are more vulnerable to further
increase of calcium concentration (Goos et al., 2007; Jaiswal et al.,
2009). These findings are supported by similar observations in
G93A transgenic mice (Jaiswal and Keller, 2009). The reduction
in calcium uptake does not seem the consequence of disturbed
mitochondrial membrane potential. Conversely, it could be
related to a differential expression of transporters and regulatory
proteins involved in calcium handling, an hypothesis proposed to
explain the selective vulnerability of spinal cordmotor neurons to
calcium (Fuchs et al., 2013).
Novel in vivo and in vitro experiments are required to
investigate whether these mechanisms are directly influenced
by altered IMS composition, primed by mutant SOD1
accumulation, or by impaired mitochondrial transport resulting
from aberrant deposition of mutant SOD1 onto OMM.
In parallel, translational studies are mandatory to challenge
the therapeutic potential of the targets observed to influence
SOD1 misplacing.
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